Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The description for **Sulfamethizole + phenazopyridine** is: **Sulfamethizole + phenazopyridine** is a pharmaceutical combination of a sulfonamide antibacterial (sulfamethizole) and a urinary tract analgesic (phenazopyridine). Sulfamethizole acts as a bacteriostatic agent by inhibiting bacterial dihydropteroate synthase, thereby interfering with folate synthesis and ultimately inhibiting bacterial DNA replication[10]. Phenazopyridine acts locally as an analgesic on the mucosa of the urinary tract to relieve urinary pain, burning, and discomfort, but does not have antibacterial activity[2][4][9]. This combination is used primarily for the treatment of urinary tract infections (UTIs), with sulfamethizole targeting the underlying bacterial infection and phenazopyridine providing symptomatic relief. The combination is intended for short-term use, with phenazopyridine typically limited to a maximum of 2 days of therapy to minimize risk of adverse effects[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfamethizole + phenazopyridine.